Baricitinib shows promise in pediatric patients with moderate-to-severe atopic dermatitisApril 18, 2023Atopic Dermatitis
Phase 3 trials support lebrikizumab for moderate-to-severe atopic dermatitisApril 18, 2023Atopic Dermatitis
Dermatology NewsWhat are the clinical implications of recent skin dysbiosis discoveries?April 6, 2023Atopic DermatitisMedical DermatologyPediatrics
Commentary: IL-31 inhibitor, e-cigarettes, and upadacitinib in AD, April 2023March 29, 2023Atopic Dermatitis
Dermatology NewsJAK inhibitor ivarmacitinib shows efficacy for atopic dermatitis in a pivotal trialMarch 29, 2023Atopic DermatitisMixed Topics
Dermatology NewsTopical delgocitinib shows promise for chronic hand eczema, pivotal trial showsMarch 27, 2023Atopic Dermatitis
Dermatology NewsNew data forecast more oral PDE4 inhibitors for psoriasisMarch 27, 2023PsoriasisAtopic DermatitisPsoriatic Arthritis
Skin biomarkers in infants aged 2 months predictive of future atopic dermatitis onsetMarch 23, 2023Atopic Dermatitis
Crisaborole improves sleep outcomes in pediatric mild-to-moderate atopic dermatitisMarch 23, 2023Atopic Dermatitis
Atopic dermatitis is positively linked with the risk for gastroesophageal reflux diseaseMarch 23, 2023Atopic Dermatitis
Season of birth influences the risk for atopic dermatitis in early infancyMarch 23, 2023Atopic Dermatitis
Pruritus reduction crucial for improving other inflammatory symptoms in nemolizumab-treated atopic dermatitisMarch 23, 2023Atopic Dermatitis
Study reveals an association between atopic dermatitis and e-cigarette use among US adultsMarch 23, 2023Atopic Dermatitis
